Literature DB >> 15856157

[Transurethral resection for benign prostatic hyperplasia. current developments].

M Alschibaja1, F May, U Treiber, R Paul, R Hartung.   

Abstract

Transurethral resection of the prostate still represents the "gold standard" in surgical treatment of symptomatic benign prostatic enlargement (BPE). New demands were made on transurethral electrosurgery with the appearance of alternative, minimal invasive procedures. Bleeding complications had to be reduced. Different attempts were made to improve the conventional TURP. Band loops and roller bars were developed in order to gain a more effective coagulation during the cutting process by a larger tissue contact. Major advances could be achieved by modifications of the high-frequency generator. Improved procedures like the "Coagulating-Intermittent-Cutting" (CIC), the "Instant-Response-", as well as the "Dry-Cut-Technology" combine cutting and coagulating effects to realize lowered bleeding and an efficient resection process. The introduction of bipolar currency flow opens the possibility of conventional TUR-P with saline solutions and thus to the theoretical avoidance of the TUR-syndrome. By the neoadjuvant use of 5alpha-reductase-inhibitors before planned TUR-P, bleeding- and irrigation fluid absorption should be reduced by lowering perfusion and the size of the prostate. Regarding these innovative approaches which improve the surgical standard and minimize the risk of perioperative complications, transurethral electrosurgery remains the method of choice in instrumental therapy of symptomatic BPE. In the future efficacy and costs will be comparable to those of the transurethral laser-resection or laser-vaporisation.

Entities:  

Mesh:

Year:  2005        PMID: 15856157     DOI: 10.1007/s00120-005-0802-z

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  25 in total

1.  Coagulating intermittent cutting. Improved high-frequency surgery in transurethral prostatectomy.

Authors:  R Hartung; H Leyh; C Liapi; K Fastenmeier; M Barba
Journal:  Eur Urol       Date:  2001-06       Impact factor: 20.096

Review 2.  Electrocautery: principles and practice.

Authors:  M Barba; K Fastenmeier; R Hartung
Journal:  J Endourol       Date:  2003-10       Impact factor: 2.942

3.  Safer transurethral resection of the prostate: coagulating intermittent cutting reduces hemostatic complications.

Authors:  Andreas P Berger; Walter Wirtenberger; Jasmin Bektic; Hannes Steiner; Robert Spranger; Georg Bartsch; Wolfgang Horninger
Journal:  J Urol       Date:  2004-01       Impact factor: 7.450

4.  Rotoresect: new technique for resection of the prostate: experimental phase.

Authors:  M S Michel; K U Köhrmann; A Weber; A W Krautschick; P Alken
Journal:  J Endourol       Date:  1996-10       Impact factor: 2.942

5.  Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options.

Authors:  G Schatzl; S Madersbacher; B Djavan; T Lang; M Marberger
Journal:  Eur Urol       Date:  2000-06       Impact factor: 20.096

Review 6.  Electrovaporization of the prostate.

Authors:  A Tewari; P Narayan
Journal:  Br J Urol       Date:  1996-11

7.  Rotoresect for bloodless transurethral resection of the prostate: a 4-year follow-up.

Authors:  M S Michel; T Knoll; L Trojan; K U Köhrmann; P Alken
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

8.  Transurethral electrovaporization of the prostate vs. transurethral resection. Results of a multicentric, randomized clinical study on 150 patients.

Authors:  M Gallucci; P Puppo; M Perachino; P Fortunato; G Muto; G Breda; A Mandressi; G Comeri; C Boccafoschi; F Francesca; S Guazzieri; G L Pappagallo
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

9.  Long-term results following transurethral resection of the prostate.

Authors:  U Zwergel; B Wullich; U Lindenmeir; V Rohde; T Zwergel
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

10.  Advantages of transurethral rotoresection versus standard transurethral resection in the management of benign hyperplasia of the prostate.

Authors:  Iakov D Kan; Sergei A Kirillov; Vitalii V Tedeev
Journal:  J Endourol       Date:  2003-11       Impact factor: 2.942

View more
  8 in total

1.  [Benign prostate hyperplasia].

Authors:  U Jonas; A I Gabouev; T R W Herrmann; K Höfner; M C Michel; M Alschibaja; R Hartung
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

2.  Ahead of the curve.

Authors:  David B Nash
Journal:  Popul Health Manag       Date:  2013       Impact factor: 2.459

3.  [Therapy of benign prostate syndrome (BPS): guidelines of the German Urologists (DGU)].

Authors:  R Berges; K Dreikorn; K Höfner; S Madersbacher; M C Michel; R Muschter; M Oelke; O Reich; W Rulf; C Tschuschke; U Tunn
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

4.  Effect of an employer-sponsored health and wellness program on medical cost and utilization.

Authors:  Hangsheng Liu; Katherine M Harris; Sarah Weinberger; Seth Serxner; Soeren Mattke; Ellen Exum
Journal:  Popul Health Manag       Date:  2012-07-23       Impact factor: 2.459

5.  [Functional outcome after laser vaporisation of the prostate with the KTP laser].

Authors:  M F Hamann; C Wild; C Seif; S Hautmann; K P Jünemann; P M Braun
Journal:  Urologe A       Date:  2007-05       Impact factor: 0.639

6.  [Benign prostatic syndrome (BPS). Ablative treatments].

Authors:  O Reich; M Seitz; C Gratzke; B Schlenker; A Bachmann; C Stief
Journal:  Urologe A       Date:  2006-06       Impact factor: 0.639

Review 7.  [Benign prostatic hyperplasia (BPH) : Surgical therapy options].

Authors:  O Reich; M Seitz; C Gratzke; B Schlenker; S Walther; C Stief
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

8.  Suprapubic cystostomy versus nonsuprapubic cystostomy during monopolar transurethral resection of prostate: a propensity score-matched analysis.

Authors:  Run-Qi Guo; Yi-Sen Meng; Wei Yu; Kai Zhang; Ben Xu; Yun-Xiang Xiao; Shi-Liang Wu; Bai-Nian Pan
Journal:  Asian J Androl       Date:  2018 Jan-Feb       Impact factor: 3.285

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.